Article Text

Download PDFPDF
Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients 40–79 years of age with hypertension and ⩾3 other cardiovascular (CV) risk factors, is amlodipine plus perindopril more effective than atenolol plus bendroflumethiazide for reducing CV outcomes?

Clinical Impact Ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★★☆ Cardiology ★★★★★★☆


Embedded ImageDesign

randomised controlled trial (Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm [ASCOT-BPLA]).

Embedded ImageAllocation


Embedded ImageBlinding

blinded (outcome assessors).*

Embedded ImageFollow up period

median 5.5 years.

Embedded ImageSetting

686 family practices in the Nordic countries and 32 regional centres in the UK and Ireland.

Embedded ImagePatients

19 257 patients 40–79 years of age (mean age 63 y, 77% men) who had hypertension and ⩾3 other CV risk factors. Exclusion criteria included previous myocardial infarction (MI), currently treated angina, and a cerebrovascular event …

View Full Text


  • * See glossary.

  • For correspondence: Dr B Dahlöf, Sahlgrenska University Hospital/Östra, Göteborg, Sweden. bjorn.dahlof{at}

  • Sources of funding: Pfizer and Servier Research Group.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd